Search results for "liver fibrosis"

showing 10 items of 106 documents

Prevalence and risk factors for advanced liver fibrosis in HIV/HCV-coinfected individuals

2010

Liver fibrosis HIV HCV coinfection transient elastography
researchProduct

Is the Macrophage Phenotype Determinant for Fibrosis Development?

2021

Fibrosis is a pathophysiological process of wound repair that leads to the deposit of connective tissue in the extracellular matrix. This complication is mainly associated with different pathologies affecting several organs such as lung, liver, heart, kidney, and intestine. In this fibrotic process, macrophages play an important role since they can modulate fibrosis due to their high plasticity, being able to adopt different phenotypes depending on the microenvironment in which they are found. In this review, we will try to discuss whether the macrophage phenotype exerts a pivotal role in the fibrosis development in the most important fibrotic scenarios.

Lungpulmonary fibrosisQH301-705.5business.industryCardiac fibrosiscardiac fibrosiskidney fibrosisMedicine (miscellaneous)Connective tissueReviewmedicine.diseasePhenotypeGeneral Biochemistry Genetics and Molecular BiologymacrophagesExtracellular matrixmedicine.anatomical_structureFibrosisPulmonary fibrosisintestinal fibrosisCancer researchmedicineMacrophageBiology (General)businessliver fibrosisBiomedicines
researchProduct

RNF2 Mediates Hepatic Stellate Cells Activation by Regulating ERK/p38 Signaling Pathway in LX-2 Cells

2021

The therapeutic approach of liver fibrosis is still an unsolved clinical problem worldwide. Notably, the accumulation of extracellular matrix (ECM) in the liver is mediated by the production of cytokines and growth factors, such as transforming growth factor-β1 (TGF-β1) in hepatic stellate cells (HSCs). Ring finger protein 2 (RNF2) was identified as the catalytic subunit of polycomb repressive complex 1 (PRC1), mediating the monoubiquitination of histone H2A. In recent years, a growing amount of evidence suggests that RNF2 may play an important role in multiple pathological processes involved in cancer. Here, we explored the role of RNF2 in liver fibrogenesis and its potential mechanisms. T…

MAPK/ERK pathwayGene knockdownChemistryCell growthp38 mitogen-activated protein kinasesapoptosisRNF2Cell BiologyCell biologyExtracellular matrixCell and Developmental BiologyLX-2 cellslcsh:Biology (General)Downregulation and upregulationinflammationMAPK signaling pathwayHepatic stellate cellSignal transductionlcsh:QH301-705.5Original Researchliver fibrosisDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

2018

ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportiona…

Male0301 basic medicineOncologyCandidate geneCholangitismedicine.medical_treatmentMedizinTrasplantament hepàticGenome-wide association studyKaplan-Meier EstimateLIVER FIBROSISLiver transplantationBioinformaticsSclerosingOral and gastrointestinalPrimary sclerosing cholangitis; genetics; liver transplantationCohort StudiesACTIVATION0302 clinical medicineMED/12 - GASTROENTEROLOGIAMULTIPLE2.1 Biological and endogenous factorsEPIDEMIOLOGYgeneticsAetiologyCIRRHOSISliver transplantationBilious diseases and biliousnessPrimary sclerosing cholangitisLiver Diseasedigestive oral and skin physiologyGastroenterologySingle NucleotidePrimary sclerosing cholangitiMiddle Aged3. Good healthULCERATIVE-COLITISDisease ProgressionFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyCholangitis SclerosingChronic Liver Disease and CirrhosisClinical SciencesMalalties del tracte biliarSingle-nucleotide polymorphismHEPATIC STELLATE CELLSPolymorphism Single NucleotideInternational PSC Study GroupArticlePrimary sclerosing cholangitisPaediatrics and Reproductive Medicine03 medical and health sciencesRare DiseasesClinical ResearchInternal medicineGeneticsmedicineHumansPolymorphismGENOME-WIDE ASSOCIATIONAlleleDigestive Diseases - (Gallbladder)Survival analysisProportional Hazards ModelsMALIGNANCYThe UK PSC ConsortiumTransplantationGastroenterology & Hepatologybusiness.industryProportional hazards modelmedicine.diseaseRISK LOCILogistic Models030104 developmental biology3121 General medicine internal medicine and other clinical medicinegeneticHepatic transplantationThrombospondinsDigestive DiseasesbusinessGenèticaGut
researchProduct

Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort.

2021

Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co-medicated HCV patients was evaluated. Methods We prospectively evaluated consecutive patients from 15 clinical centres participating in PITER who were treated with ELB/GZR and had been followed for at least 12 weeks after treatment. Data were prospectively collected on the use of comedications (including discontinuation, dose modification and addition of drugs) and potential DDIs with DAAs. Results Of the 356 patients with at least 12-week post-t…

Male030312 virologycombination therapytreatment experienced patientsDrug Combinationchronic hepatitis C drug drug interactions virus genotype 1 treatment experienced patients pump inhibitor use combination therapy treatment naive liver fibrosisgrazoprevir elbasvir80 and overAge FactorPharmacology (medical)Drug InteractionsProspective StudiesChronicProspective cohort studyliver fibrosisAged 80 and over0303 health sciencesAge FactorsImidazolesMiddle AgedHepatitis CDrug CombinationsInfectious DiseasesTreatment OutcomeDrug InteractionGrazoprevirCohortdrug drug interactionsFemalepump inhibitor useHumanmedicine.drugmedicine.medical_specialtyElbasvirQuinoxalinetreatment naiveelbasvirAntiviral AgentsNO03 medical and health sciencesInternal medicineQuinoxalinesmedicinechronic hepatitis CElbasvir GrazoprevirHumansImidazoleAgedBenzofuransAntiviral AgentPharmacology...business.industrygrazoprevirCarbamazepineHepatitis C Chronicmedicine.diseaseComorbidityDiscontinuationBenzofuranAge Factors; Aged; Aged 80 and over; Antiviral Agents; Benzofurans; Drug Combinations; Drug Interactions; Female; Hepatitis C Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Treatment Outcomebusinessvirus genotype 1Antiviral therapy
researchProduct

Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease.

2014

Home parenteral nutrition (PN) is associated with many complications including severe hepatobiliary dysfunction. Commercial ω-6 fatty acid-soybean based-lipid emulsions in PN may mediate long term PN associate liver disease (PNALD) whereas ω-3-fish oil parenteral emulsions have shown to reverse PNALD in children. However, its clinical effectiveness in adults has been scarcely reported. In this work, we study the role of soybean and fish oil lipid commercial emulsions on inflammatory and profibrotic liver markers in adults with long term PNALD and in in vitro cellular models. Inflammatory and profibrotic markers were measured in serum of ten adults with long term PNALD and in culture superna…

MaleLipopolysaccharideAnti-Inflammatory AgentsCell Culture Techniqueslcsh:MedicinePharmacologySoybean oilChronic Liver DiseaseLiver diseasechemistry.chemical_compoundMedicine and Health Scienceslcsh:ScienceMultidisciplinaryLiver DiseasesFatty liverMiddle AgedFish oilLiver FibrosisFemalemedicine.symptomParenteral Nutrition HomeResearch ArticleAdultFat Emulsions Intravenousfood.ingredientEpithelial-Mesenchymal Transitionmedicine.drug_classImmunologyInflammationGastroenterology and HepatologyAnti-inflammatoryImmunomodulationCicatrixfoodFish OilsFatty Acids Omega-6medicineHumansTriglyceridesAgedNutritionbusiness.industrylcsh:RBiology and Life Sciencesmedicine.diseaseNutritional DiseasesSoybean OilParenteral nutritionchemistryImmunologylcsh:QbusinessPloS one
researchProduct

Transient Elastography-Based Liver Stiffness Age-Dependently Increases in Children

2016

Background and Aims Pediatric use of liver transient elastography (TE) is attractive for its non-invasiveness, but reference values have not been established. We aimed to determine reference values for TE in children. Methods In pediatric patients (1 to 18 years), TE (FibroScan®) with an M probe was used for both liver stiffness measurement (LSM) and measurement of hepatic fat deposition by using a controlled attenuation parameter (CAP). The patients were divided into three relevant age groups: preschoolers (1 to 5 years), elementary school children (6 to 11 years), and adolescents (12 to 18 years). Overweight or obese patients or those with known liver disease, elevated serum liver enzymes…

MalePercentilePhysiologylcsh:MedicineSocial SciencesOverweightAdolescentsPediatricsGastroenterologyLiver disease0302 clinical medicineSociologyReference ValuesRisk FactorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceChildSchoolsMultidisciplinaryLiver DiseasesFatty liverLiverPhysiological ParametersChild PreschoolElasticity Imaging TechniquesLiver FibrosisFemale030211 gastroenterology & hepatologymedicine.symptomResearch Articlemedicine.medical_specialtyChildhood ObesityAdolescentGastroenterology and HepatologyChildhood obesityEducation03 medical and health sciencesLiver stiffnessInternal medicinemedicineHumansObesitybusiness.industrylcsh:RBody WeightInfantBiology and Life SciencesEchogenicitymedicine.diseaseFatty LiverAge GroupsPeople and Placeslcsh:QPopulation GroupingsTransient elastographybusinessPLOS ONE
researchProduct

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

2019

Background The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study. Methods HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates. Results 1,062 patients were included from 2005 to 2015 …

MaleRNA virusesSustained Virologic ResponseMetabolic disordersSocial SciencesHIV InfectionsHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicineImmunodeficiency VirusesRisk FactorsPsychologyAlcohol consumptionProspective Studies030212 general & internal medicineProspective cohort studyPathology and laboratory medicineMultidisciplinaryDeath ratesCoinfectionHepatitis C virusMortality rateQHazard ratioRvirus diseasesHepatitis CMiddle AgedMedical microbiologyAddicts3. Good healthLiverDrug usersVirusesCohortElasticity Imaging TechniquesMedicineFemale030211 gastroenterology & hepatologyFrancePathogensResearch ArticleCohort studyAdultmedicine.medical_specialtyScienceHepatitis C virusLiver fibrosisAddictionGastroenterology and HepatologyAntiviral AgentsMicrobiology03 medical and health sciencesPopulation MetricsInternal medicineRetrovirusesmedicineHumansMortalityLiver diseasesProportional Hazards ModelsNutritionMedicine and health sciencesBiology and life sciencesFlavivirusesPopulation Biologybusiness.industryProportional hazards modelLentivirusOrganismsViral pathogensHIVHepatitis C Chronicmedicine.diseaseHepatitis virusesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessPLOS ONE
researchProduct

Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcohol…

2017

BACKGROUND: No study evaluated vascular health markers in subjects with non-alcoholic fatty liver disease (NAFLD) through a combined analysis of reactive hyperemia peripheral arterial tonometry (RH-PAT) and arterial stiffness indexes. AIM OF THE STUDY: We aimed to assess whether NAFLD and its histological severity are associated with impairment of arterial stiffness and RH-PAT indexes in a mixed cohort of patients with biopsy-proven NAFLD. MATERIALS AND METHODS: The Kleiner classification was used to grade NAFLD grade. Pulse wave velocity (PWV) and augmentation index (Aix) were used as markers of arterial stiffness, whereas endothelial function was assessed using reactive hyperemia index (R…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaBiopsyEndocrinology Diabetes and MetabolismHistopathology; Liver fibrosis; Non-alcoholic fatty liver disease030204 cardiovascular system & hematologySeverity of Illness IndexLiver diseaseCognition0302 clinical medicineRisk FactorsPrevalencePulse wave velocityOriginal InvestigationFatty liverMiddle AgedMental Status and Dementia TestsItalyLiverCardiovascular DiseasesCardiologyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyManometryLiver fibrosisHistopathologyHyperemiaPulse Wave Analysis03 medical and health sciencesVascular StiffnessDiabetes mellitusInternal medicineInternal MedicinemedicineHumansReactive hyperemiaAgedbusiness.industryLiver fibrosinutritional and metabolic diseasesmedicine.diseasedigestive system diseasesCross-Sectional StudiesBlood pressurelcsh:RC666-701Case-Control StudiesArterial stiffnessSteatohepatitisCognition Disordersbusiness030217 neurology & neurosurgeryNon-alcoholic fatty liver diseaseCardiovascular Diabetology
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct